Financials
| Annual Financial Report | Feb. 18, 2025 |
| 2024 Annual Report & 20-F Information | Feb. 18, 2025 |
| Final Results | Feb. 06, 2025 |
| 9M and Q3 2024 Results | Nov. 12, 2024 |
| Half-year Report | Jul. 25, 2024 |
| 1st Quarter Results | Apr. 25, 2024 |
| 9M and Q3 2023 results | Nov. 09, 2023 |
Proxies
| Special Business Approved at AGM | Apr. 12, 2024 |
| Proxy Form for 2024 AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Special Business Approved at AGM | Apr. 27, 2023 |
| Result of AGM | Apr. 27, 2023 |
| Notice of AGM | Mar. 22, 2023 |
Ownership Update
| Holding(s) in Company | Mar. 12, 2025 |
| Director/PDMR Shareholding | Mar. 07, 2025 |
| Director/PDMR Shareholding | Mar. 06, 2025 |
| Director/PDMR Shareholding | Mar. 05, 2025 |
| Holding(s) in Company | Feb. 18, 2025 |
| Director/PDMR Shareholding | Nov. 20, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |
Announcements
| Total Voting Rights | Apr. 01, 2025 |
| Calquence recommended for EU approval in 1L MCL | Mar. 31, 2025 |
| Imfinzi approved in the US for bladder cancer | Mar. 31, 2025 |
| AZN invests $2.5bn in Beijing R&D & manufacturing | Mar. 21, 2025 |
| Eneboparatide Phase III trial met primary endpoint | Mar. 17, 2025 |
| Imfinzi approved in EU for limited-stage SCLC | Mar. 17, 2025 |
| AstraZeneca to acquire EsoBiotec | Mar. 17, 2025 |
Prospectuses
| AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
| AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
| AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
| AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
| AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |